{"id":670292,"date":"2023-09-29T20:08:01","date_gmt":"2023-09-29T20:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=670292"},"modified":"2023-09-29T20:08:01","modified_gmt":"2023-09-29T20:08:01","slug":"chronic-rhinosinusitis-without-nasal-polyps-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-lyra-therapeutics-insmed-sanofi","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-rhinosinusitis-without-nasal-polyps-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-lyra-therapeutics-insmed-sanofi_670292.html","title":{"rendered":"Chronic Rhinosinusitis Without Nasal Polyps  Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies &#8211; Lyra Therapeutics, Insmed, Sanofi"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Rhinosinusitis Without Nasal Polyps  Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Lyra Therapeutics, Insmed, Sanofi\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Chronic Rhinosinusitis Without Nasal Polyps  Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Lyra Therapeutics, Insmed, Sanofi\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cChronic Rhinosinusitis Without Nasal Polyps (CRSsNP) \u2013 Market Insights, Epidemiology, and Market Forecast \u2013 2032\u201d report delivers an in-depth understanding of the CRSsNP, historical and forecasted epidemiology and the chronic rhinosinusitis without nasal polyps market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-rhinosinusitis-without-nasal-polyps-crssnp-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) &ndash; Market Insights, Epidemiology, and Market Forecast &ndash; 2032<\/a><\/strong>&rdquo; report delivers an in-depth understanding of the CRSsNP, historical and forecasted epidemiology and the chronic rhinosinusitis without nasal polyps market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Rhinosinusitis Without Nasal Polyps Key Highlights&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Companies working in the Chronic Rhinosinusitis Without Nasal Polyps&nbsp; market include Lyra Therapeutics, Insmed, Sanofi, Regeneron Pharmaceuticals, and many others.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Therapies included in the Chronic Rhinosinusitis Without Nasal Polyps&nbsp; market include XHANCE (fluticasone propionate), LYR-210, and many others&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Rhinosinusitis Without Nasal Polyps Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) is a prevalent and chronic medical condition characterized by inflammation and swelling of the nasal passages and paranasal sinuses, but notably, it does not involve the presence of nasal polyps. Individuals with chronic rhinosinusitis without nasal polyps often experience symptoms such as nasal congestion, difficulty breathing through the nose, facial pain or pressure, reduced sense of smell (hyposmia), and a persistent discharge from the nose. These symptoms typically last more than 12 weeks, making it a chronic condition requiring proper management.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/ac939451b5833c12200a8057f26e1ee6.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Rhinosinusitis Without Nasal Polyps Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">In 2022, among the 7MM, the US recorded the highest number of prevalent cases of Chronic Rhinosinusitis (CRS), with approximately 31 million cases. Across all the 7MM countries, the total number of prevalent CRS cases was approximately 71 million, and these cases are projected to increase by 2032.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In 2022, there were an estimated 9 million diagnosed cases of CRS out of a total of 31 million prevalent cases in EU4 and the UK.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DelveInsight&rsquo;s analysis indicates that approximately 81% of the total diagnosed cases of CRS in the 7MM were diagnosed as chronic rhinosinusitis without nasal polyps accounting for about 17 million cases in the 7MM, among which the US accounted for 51% of the cases.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-rhinosinusitis-without-nasal-polyps-crssnp-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Chronic Rhinosinusitis Without Nasal Polyps Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Report Covers the Chronic Rhinosinusitis Without Nasal Polyps Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Rhinosinusitis Without Nasal polyps Prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Rhinosinusitis Without Nasal Polyps Incident cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Rhinosinusitis Without Nasal Polyps Treatment cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Rhinosinusitis Without Nasal Polyps Diagnosed cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Rhinosinusitis Without Nasal Polyps Market Outlook&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Chronic Rhinosinusitis Without Nasal Polyps has a diverse treatment classification associated with the disease landscape. The primary goal of treatment for chronic rhinosinusitis without nasal polyps is to reduce inflammation, control symptoms, and improve the patient&rsquo;s quality of life. Antibiotics and corticosteroids are major revenue generators in the current treatment landscape. The use of antibiotics and corticosteroids (intranasal and oral) is guided by clinical practice guidelines, which provide evidence-based recommendations to healthcare professionals to manage CRSsNP.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Companies Working in the Chronic Rhinosinusitis Without Nasal Polyps Market&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lyra Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Insmed<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sanofi<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Regeneron Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Rhinosinusitis Without Nasal PolypsTherapies Covered and Analyzed in the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">XHANCE (fluticasone propionate)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">LYR-210<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-rhinosinusitis-without-nasal-polyps-crssnp-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Key Companies and Emerging Therapies in the Chronic Rhinosinusitis Without Nasal Polyps Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Chronic Rhinosinusitis Without Nasal Polyps&nbsp; Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Executive Summary of Chronic Rhinosinusitis Without Nasal Polyps&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Chronic Rhinosinusitis Without Nasal Polyps&nbsp; Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Chronic Rhinosinusitis Without Nasal Polyps&nbsp; Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-rhinosinusitis-without-nasal-polyps-crssnp-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Chronic Rhinosinusitis Without Nasal Polyps Market Outlook<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-rhinosinusitis-without-nasal-polyps-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-lyra-therapeutics-insmed-sanofi\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-rhinosinusitis-without-nasal-polyps-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-lyra-therapeutics-insmed-sanofi\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cChronic Rhinosinusitis Without Nasal Polyps (CRSsNP) \u2013 Market Insights, Epidemiology, and Market Forecast \u2013 2032\u201d report delivers an in-depth understanding of the CRSsNP, historical and forecasted epidemiology and the chronic rhinosinusitis without nasal polyps market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-rhinosinusitis-without-nasal-polyps-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-lyra-therapeutics-insmed-sanofi_670292.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-670292","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/670292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=670292"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/670292\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=670292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=670292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=670292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}